Our findings are in line with previous findings in CLL cells [38] where treatment of CLL cells with BAY61-3606 caused caspase-3 activation, cleavage of PARP-1 and loss of mitochondrial potential. The gene discussed is PARP1; the disease is B-cell chronic lymphocytic leukemia.